✓ Translated by DotMD AI Clinical Council Source: International journal of radiation oncology, biology, physics • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37023988 ↗

Phase III Randomized Trial: Dosimetric Evaluation of Organs at Risk From SAVE Protocol

Original Paper Title: “Dosimetric Evaluation of Organs at Risk From SAVE Protocol”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Experimental short-course VCB of 11 Gy × 2 fx to the surface provides a comparable biologically effective dose to SOC courses. Experimental short-course VCB was found to reduce or be comparable to D2cc and D0.1cc EQD2 3 doses to rectum, bladder, sigmoid, small bowel, and urethra critical structures.
  • Study Design & Sample: Phase III Randomized Trial published in International journal of radiation oncology, biology, physics (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in International journal of radiation oncology, biology, physics (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: The objective of this work was to evaluate dosimetric characteristics to organs at risk (OARs) from short-course adjuvant vaginal cuff brachytherapy (VCB) in early endometrial cancer compared with standard of care (SOC) in a multi-institutional prospective randomized trial. Key clinical takeaway: Experimental short-course VCB of 11 Gy × 2 fx to the surface provides a comparable biologically effective dose to SOC courses. Experimental short-course VCB was found to reduce or be comparable to D2cc and D0.1cc...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (International journal of radiation oncology, biology, physics, 2023-09-01; Phase III Randomized Trial; Rigor 82/100): Experimental short-course VCB of 11 Gy × 2 fx to the surface provides a comparable biologically effective dose to SOC courses. Experimental short-course VCB was found to reduce or be comparable to D2cc and D0.1cc EQD2 3 doses to rectum, bladder, sigmoid, small bowel, and urethra critical structures.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: phenytoin-toxicity → Condition: polydipsia →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37023988: Phase III Randomized Trial: Dosimetric Evaluation of Organs at Risk From SAVE Protocol

3 of 3 Free Questions Remaining